News

markets. businessinsider. com
markets. businessinsider. com > news > stocks > palvella-therapeutics-to-present-qtorin-rapamycin-results-from-phase-3-selva-and-phase-2-toiva-studies-at-the-international-society-for-the-study-of-vascular-anomalies-world-congress-2026-1036037533

Palvella Therapeutics to Present QTORIN" Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026

1+ mon, 1+ week ago  (248+ words) James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children's Hospital of Philadelphia to present clinical results on Wednesday, May 20, 2026, at 4: 30 p. m. ET WAYNE, Pa. , April. .. Palvella Therapeutics to Present QTORIN" Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA…...

Symbols: nasdaq:pvla
Med City News
medcitynews. com > 2026 > 04 > intellia-crispr-in-vivo-gene-editing-hereditary-angioedema-hae-rare-disease-ntla

Intellia's Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med

4+ week, 1+ day ago  (247+ words) Intellia Therapeutics" lonvo-z uses CRISPR to inactivate a gene in the liver to reduce levels of a protein key to the swelling attacks from the rare disease hereditary angioedema. Intellia has filed a regulatory submission for this genetic medicine, which…...

Symbols: lonvo-z
CNBC
cnbc. com > 04/27/2026 > crispr-gene-editing-intellia-trial. html

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

1+ mon, 1+ hour ago  (449+ words) Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U. S. Food and…...

Symbols: attr-cm,lonvo-z,nasdaq:ntla
Los Angeles Business Journal
labusinessjournal. com > featured > amgen-drug-reviewed-amid-deaths

Amgen Drug Reviewed Amid Deaths

1+ day, 14+ hour ago  (563+ words) The deaths of 20 patients in Japan have prompted scrutiny of a drug produced by Thousand Oaks-based Amgen. Sales of the problematic Amgen Inc. drug Tavneos resumed late last week in Japan with a new warning label after several patient deaths…...

Symbols: nasdaq:amgn,btc-usd
STAT
statnews. com > 01/16/2025 > huntingtons-disease-new-research-into-cause-of-brain-ravaging-condition

Studies reveal a new biology of Huntington's, renewing drugmaker interest in therapies

3+ week, 5+ day ago  (231+ words) STAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts, and opinion pieces. We tell our stories…...

Symbols: nasdaq:qure
Yahoo Finance
finance. yahoo. com > sectors > healthcare > articles > nomoslogic-brings-deterministic-molecular-medicine-123100009. html

Nomos Logic Brings Deterministic Molecular Medicine Infrastructure to BIO International Convention 2026 as Adverse Drug Reactions Continue to Cost $30 Billion and 100, 000 American Lives Each Year

6+ day, 4+ hour ago  (167+ words) Salt Lake City-based infrastructure company addresses the architectural failure underneath three decades of population-averaged precision medicine, with founder and Business Development team available for meetings June 22-25 at the Bio Utah pavilion "Adverse drug reactions cost the American healthcare system thirty…...

Symbols: btc-usd
Science Daily
sciencedaily. com > releases > 2025 > 04 > 250411175449. htm

New key genes in Parkinson's disease identified using CRISPR technology

6+ hour, 56+ min ago  (490+ words) A longstanding mystery in Parkinson's disease research has been why some individuals carrying pathogenic variants that increase their risk of PD go on to develop the disease, while others who also carry such variants do not. The prevailing theory has…...

Symbols: btc-usd,ipsc-da,limp-2
markets. businessinsider. com
markets. businessinsider. com > news > stocks > traws-pharma-announces-antiviral-program-targeting-ongoing-hantavirus-and-ebola-virus-disease-outbreaks-1036197994

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

1+ hour, 56+ min ago  (160+ words) Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option to manage existing and future outbreaks Interactions planned with the US Centers for Disease Control and Prevention (CDC), and ongoing with the…...

Symbols: nasdaq:traw,asx:ila
Brattleboro Reformer
reformer. com > scott-signs-rare-disease-advisory-council-into-law > article_60126f00-cb16-44ab-baf2-dffd984cdba1. html

Scott signs Rare Disease Advisory Council into law

2+ day, 17+ hour ago  (372+ words) Gov. Phil Scott speaks at a press conference on Thursday, April 23. MONTPELIER " The National Organization for Rare Disorders celebrated the signing of House Bill 46 into law by Governor Phil Scott, establishing a Rare Disease Advisory Council (RDAC) in Vermont. This…...

Symbols: gsy.to
markets. businessinsider. com
markets. businessinsider. com > news > stocks > brain-cancer-canada-invests-50-000-in-promising-immunotherapy-breakthrough-targeting-one-of-the-most-aggressive-brain-tumours-1036193721

Brain Cancer Canada Invests $50, 000 in Promising Immunotherapy Breakthrough Targeting One of the Most Aggressive Brain Tumours

1+ day, 2+ hour ago  (81+ words) Brain Cancer Canada (BCC), Canada's only 100% volunteer-driven charity dedicated exclusively to funding brain cancer research nationwide is proud to award $50, 000 to an exciting research project led. .. About Brain Cancer Canada As a fully volunteer-based organization, Brain Cancer Canada ensures that…...

Symbols: nasdaq:cnsp